0,05. Доказательная медицина от магии до поисков бессмертия Талантов Петр
Харламова Ф. С., Кладова О. В., Сергеева Э. М. и др. Клиническая эффективность препарата Кагоцел® при гриппе и ОРВИ у детей с 2 до 6 лет // Детские инфекции. 2010. № 4. С. 34–41.
Вартанян Р. В., Сергеева Э. М., Чешик С. Г. Оценка терапевтической эффективности препарата Кагоцел® у детей младшего и дошкольного возраста с острыми респираторными вирусными инфекциями // Детские инфекции. 2011. № 1. С. 36–41.
Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE seeding trial: A review of internal documents // Annals of Internal Medicine. 2008. Vol. 149. № 4. P. 251–258.
Krimsky S., Rothenberg L. S., Stott P., Kyle G. Scientific journals and their authors’ financial interests: A pilot study // Psychotherapy and psychoomatics. 1998. July-October. Vol. 67. № 4–5. P. 194–201.
Papanikolaou G. N., Baltogianni M. S., Contopoulos-Ioannidis D. G. et al. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions // BMC medical research methodology. 2001. Vol. P. 3.
Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? // PLoS Medicine. 2007. Vol. 4. № 9, e286.
Mirowski P., Van Horn R. The contract research organization and the commercialization of scientific research // Social studies of science. 2005. August. Vol. 35. № 4. P. 503–548.
Gubler A. Alternating hemiplegia, a sign of pontine lesion, and documentation of the proof of the facial decussation / Wolf J. K. (ed.). The Classical Brainstem Syndromes. Springfield: Charles C Thomas, 1971. P. 9–13.
Austin S. C., Stolley P. D., Lasky T. The history of malariotherapy for neurosyphilis // JAMA. 1992. Vol. 268. № 4. P. 516–519.
Valenstein E. S. Great and desparate cures: The rise and decline of psychosurgery and other radical treatments for mental illness. New York: Basic Books, 1986.
EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial // The New England journal of medicine. 1985. November 7. Vol. 313. № 19. P. 1191–1200.
Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.
Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in america’s worst drug disaster. New York: Simon and Schuster, 1995.
Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized trials // JAMA. 1993. October 6. Vol. 270. № 13. P. 1589–1595.
Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.
Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al. Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1, h4534.
Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.
Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4. P. I26–13I.
Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’ in developed countries // Journal of epidemiology and community health. 1978. September. Vol. 32. № 3. P. 200–205.
Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.
Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386. № 9995. P. 743–800.
Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? // Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.
Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol. 279. № 15. P. 1200–1205.
Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol. 284. № 4. P. 483–485.
Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.
Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.
Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model // Journal of the American Pharmaceutical Association. 2001. March/April. Vol. 41. № 2. P. 192–199.
Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–47.
Sturkenboom M. C., Romano F., Simon G., Correa-Leite M. L., Villa M. et al. The iatrogenic costs of NSAID therapy: a population study // Arthritis and rheumatism. 2002 April 15. Vol. 47. № 2. P. 132–140.
Weingart S. N., Wilson R. McL., Gibberd R. W., Harrison B. Epidemiology of medical error // BMJ. 2000. March 18. Vol. 320. № 7237. P. 774–777.
Hayward R. A., Hofer T. P. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer // JAMA. 2001. Vol. 286. № 4. P. 415–420.
Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // The Journal of urology. 1994. January. Vol. 151. № 1. P. 54–61.
Araujo A. B., Johannes C. B., Feldman H. A., Derby C. A., McKinlay J. B. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts male aging study // American Journal of Epidemiology. 2000. September 15. Vol. 152. № 6. P. 533–541.
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction // PLoS Medicine. 2006. Vol. 3. № 4, e132.
Sample I. Viagra: The profitable pill // The Guardian. 2009. November 16.
Moynihan R. The making of a disease: female sexual dysfunction // BMJ. 2003. January 4. Vol. 326. № 7379. P. 45–47.
Critser G. Generation Rx: How prescription drugs are altering American lives, minds, and bodies. Boston: Houghton-Mifflin, 2005.
Laumann E. O., Paik A., Rosen R. C. Sexual dysfunction in the United States: prevalence and predictors // JAMA. 1999. Vol. 281. № 6. P. 537–544.
Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering // BMJ. 2002. April 13. Vol. 324. № 7342. P. 886–891.
Clark D. Between hope and acceptance: the medicalisation of dying // BMJ. 2002. April 13. Vol. 324. № 7342. P. 905–907.
Gilbert D., Walley T., New B. Lifestyle medicines // BMJ. 2000. November 25. Vol. 321. № 7272. P. 1341–1344.
Maggini M., Vanacore N., Raschetti R. Cholinesterase inhibitors: drugs looking for a disease? // PLoS Medicine. 2006. Vol. 3. № 4, e140.
Phillips C. B. Medicine goes to school: Teachers as sickness brokers for ADHD // PLoS Medicine. 2006. Vol. 3. № 4, e182.
Healy D. The latest mania: Selling bipolar disorder // PLoS Medicine. 2006. Vol. 3. № 5, e236.
Scott S. The medicalisation of shyness: from social misfits to social fitness // Sociology of Health & Illness. 2006. Vol. 28. № 2. P. 133–153.
Wolinsky H. Disease mongering and drug marketing // EMBO reports 2005. Vol. 6. № 7. P. 612–614.
Woloshin S., Schwartz L. M. Giving legs to restless legs: A case study of How the media helps make people sick // PLoS Medicine. 2006. Vol. 3. № 4, e170.
Gagnon M.-A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States // PLoS Medicine. 2008. Vol. 5. № 1, e1.
Branding the cure: a consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe. London: Consumers International, 2006.
Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature // Hastings Center Report. 2016. July/August. Vol. 46. № 4. P. 31–37.
Giannakakis I. A., Ioannidis J. P. A. Arabian nights – 1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report // BMJ. 2000. December 23. Vol. 321. № 7276. P. 1563–1564.
Donohue J. M., Cevasco M., Rosenthal M. B. A decade of direct-to-consumer advertising of prescription drugs // The New England journal of medicine. 2007. Vol. 357. № 7. P. 673–681.
Applbaum K. Is marketing the enemy of pharmaceutical innovation? // Hastings Center Report. 2009. July-August. Vol. 39. № 4. P. 13–17.
Ioannidis J. P. A. Mega-trials for blockbusters // JAMA. 2013. January 16. Vol. 309. № 3. P. 239–240.
Moffatt B., Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles // Perspectives in Biology and Medicine. 2007.·February. Vol. 50. № 1. P. 18–31.
Goldbloom D. S. Physicians and the pharmaceutical industry // CPA Bulletin de l’APC. 2003. October. P. 3–4.
Goldbloom D. S. Les mdecins et l’industrie pharmaceutique // CPA Bulletin de l’APC. 2003. October. P. 4–5.
Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? // JAMA. 2000. Vol. 283. № 3. P. 373–380.
Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch // Chest. 1992. Vol. 102. № 270–273.
Grande D., Frosch D. L., Perkins A. W., Kahn B. E. Effect of exposure to small pharmaceutical promotional items on treatment preferences // Archives of Internal Medicine. 2009. Vol. 169. № 9. P. 887–893.
Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a systematic review // BMJ Quality & Safety. 2005. Vol. 14. P. 246–250.
Frosch D. L., Krueger P. M., Hornik R. C., Cronholm P. F., Barg F. K. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising // Annals of family medicine. 2007. January-February. Vol. 5. № 1. P. 6–13.
Ventola C. L. Direct-to-consumer pharmaceutical advertising. Therapeutic or Toxic? // P & T: a peer-reviewed journal for formulary management. 2011. October. Vol. 36. № 10. P. 669–684.
Frosch D. L., Grande D., Tarn D. M., Kravitz R. L. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising // American journal of public health. 2010. January. Vol. 100. № 1. P. 24–32.
Experimental evaluation of the impact of distraction on consumer understanding of risk and benefit information in direct-to-consumer prescription drug television advertisements. 2011. June.
Grimes T. Mild auditory-visual dissonance in television news may exceed viewer attentional capacity // Human Communication Research. 1991. December 1. Vol. 18. № 2. P. 268–298.
Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R. et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial // JAMA. 2005. April 27. Vol. 293. № 16. P. 1995–2002.
Mintzes B., Barer M. L., Kravitz R. L., Kazanjian A., Bassett K., Lexchin J. et al. Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: two site cross sectional survey // British Medical Journal. 2002. Vol. 324. № 7332. P. 278–279.
Hochhauser M. Is this a seeding trial? // Journal of Clinical Research Best Practices. 2009. June. Vol. 5. № 6.
Vedula S. S., Bero L., Scherer R. W., Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use // The New England Journal of Medicine. 2009. № 20. Vol. 361. P. 1963–1971.
Sox H. C., Rennie D. Seeding trials: just say “No” // Annals of Internal Medicine (Editorial). 2008. August 19. Vol. 149. № 4. P. 279–280.
Kuriya B., Schneid E. C., Bell C. M. Quality of pharmaceutical industry press releases based on original research // PLoS ONE. 2008. Vol. 3. № 7, e2828.
Woloshin S., Schwartz L. M. Press releases: translating research into news // JAMA. 2002. Vol. 287. № 21. P. 2856–2858.
Yavchitz A., Boutron I., Bafeta A., Marroun I., Charles P., Mantz J. et al. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study // PLoS Med. 2012. Vol. 9. № 9, e1001308.
Welch H. G., Black W. C. Overdiagnosis in Cancer // Journal of the National Cancer Institute. 2010. May 5. Vol. 102. № 9. P. 605–613.
Барчук А., Талантов П. Война на опережение. Скрининг не станет очередной панацеей от рака, нужно менять привычки людей // Новая газета. 2018. 17 сентября. № 102.
Marmot M. G., Altman D. G., Cameron D. A., Dewar J. A., Thompson S. G., Wilcox M. The benefits and harms of breast cancer screening: an independent review // British Journal of Cancer. 2013. June 11. Vol. 108. № 11. P. 2205–2240.
Gtzsche P. C., Nielsen M. Screening for breast cancer with mammography (Review). Cochrane Database of Systematic Reviews. 2011. № 4.
Yaffe M. J., Mainprize J. G. Risk of radiation-induced breast cancer from mammographic screening // Radiology. 2011. January. Vol. 258. № 1. P. 98–105.
WHO position paper on mammography screening. World Health Organization, 2014.
Schroder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized european study // The New England Journal of Medicine. 2009. Vol. 360. № 13. P. 1320–1328.
Draisma G., Boer R., Otto S. J. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer // Journal of the National Cancer Institute. 2003. June 18. Vol. 95. № 12. P. 868–878.
Gillies D. Hempelian and Kuhnian approaches in the philosophy of medicine: the Semmelweis Case // Studies in history and philosophy of biological and biomedical sciences. 2005. March. Vol. 36. № 1. P. 159–181.
Noakes T. D., Borresen J., Hew-Butler T., Lambert M. I., Jordaan E. Semmelweis and the aetiology of puerperal sepsis 160 years on: an historical review // Epidemiology and infection. 2008. January. Vol. 136. № 1. P. 1–9.
Dunn P. M. Ignac Semmelweis (1818–1865) of Budapest and the prevention of puerperal fever // Archives of disease in childhood. Fetal and neonatal edition. 2005. Vol. 90. № 4, F345–348.
Semmelweis I. The etiology, concept, and prophylaxis of childbed fever. Madison and London: The University of Wisconsin Press, 1983.
Best M., Neuhauser D. Ignaz Semmelweis and the birth of infection control // Quality & safety in health care. 2004. June. Vol. 13. № 3. P. 233–234.
Bridson E. Y. Iatrogenic epidemics of puerperal fever in the 18th and 19th centuries // British journal of biomedical science. 1996. June. Vol. 53. № 2. P. 134–139.
Alper B. S., Hand J. A., Elliott S. G., Kinkade S., Hauan M. J., Onion D. K. et al. How much effort is needed to keep up with the literature relvant for primary care? // Journal of the Medical Library Association. 2004. October. Vol. 92. № 4. P. 429–437.
Neuman J., Korenstein D., Ross J. S., Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study // BMJ. 2011. Vol. 343. № 7827, d5621.
Khan R., Scaffidi M. A., Rumman A., Grindal A. W., Plener I. S., Grover S. C. Prevalence of financial conflicts of interest among authors of clinical guidelines related to high-revenue medications // JAMA Internal Medicine. 2018. Vol. 178. № 12. P. 1712–1715.
Combs T. R., Scott J., Jorski A., Heavener T., Vassar M. Evaluation of industry relationships among authors of clinical practice guidelines in gastroenterology // JAMA Internal Medicine. 2018. Vol. 178. № 12. P. 1711–1712.
McAlister F. A., Van Diepen S., Padwal R. S., Johnson J. A., Majumdar S. R. How evidence-based are the recommendations in evidence-based guidelines? // Plos Medicine. 2007. Vol. 4. № 8, e250.
Marciano N. J., Merlin T. L., Bessen T., Street J. M. To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? // International journal of clinical practice. 2014. June. Vol. 68. № 6. P. 761–770.
De Blois J., Fagerland M. W., Grundtvig M., Semb A. G., Gullestad L.et al. ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry // European Heart Journal. Cardiovascular Pharmacotherapy. 2015. January 1. Vol. 1. № 1. P. 31–36.
Tsugawa Y., Newhouse J. P., MacArthur J. D., Zaslavsky A. M. et al. Physician age and outcomes in elderly patients in hospital in the US: observational study // BMJ. 2017. Vol. 357. № 8106, j1797.
Nooh A., Baghdadi S., Raouf S. Induction of labour: how close to the evidence-based guidelines are we? // Journal of Obstetrics and Gynaecology. 2005. Vol. 25. № 5. P. 451–454.
Kondov K.; Sharpe P.; Mousa H. Are we following the guidelines – a retrospective analysis of compliance with evidence based protocols in cases admitted to Intensive Care Unit (ICU) from Labour Ward (LW): 1AP2–2 // European Journal of Anaesthesiology. 2012. June. Vol. 29. P. 9.
Holmes J. S., Shevrin M., Goldman, B., Share D. Translating research into practice: are physicians following evidence-based guidelines in the treatment of hypertension? // Medical Care Research and Review. 2004. Vol. 61. № 4. P. 453–473.
Gabbay J., Le May A. Evidence based guidelines or collectively constructed “mindlines”? Ethnographic study of knowledge management in primary care // BMJ. 2004. October 30. Vol. 329. № 7473. P. 1013–1018.
Andr M., Borgquist L., Foldevi M., Mlstad S. Asking for ‘rules of thumb’: a way to discover tacit knowledge in general practice // Family practice. 2002. December. Vol. 19. № 6. P. 617–622.
Andr M., Borgquist L., Mlstad S. Use of rules of thumb in the consultation in general practice – an act of balance between the individual and the general perspective // Family practice. 2003. October. Vol. 20. № 5. P. 514–519.
Зайцева Е. А. Клинический выбор врачей в крупном российском городе: опыт качественного анализа // Медицинская антропология и биоэтика. 2018. Т. 1. № 15.
Hajjaj F. M., Salek M. S., Basra M. K. A., Finlay A. Y. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice // Journal of the Royal Society of Medicine. 2010. May 1. Vol. 103. № 5. P. 178–187.
Bernheim S. M., Ross J. S., Krumholz H. M., Bradley E. H. Influence of patients’ socioeconomic status on clinical management decisions: a qualitative study // Annals of family medicine. 2008. January. Vol. 6. № 1. P. 53–59.
Arie S. Ending the French love affair with drugs // BMJ. 2012. Vol. 345. № 7879, e6996.
Prasad V., Vandross A., Toomey C., Cheung M., Rho J., Quinn S. et al. A decade of reversal: an analysis of 146 contradicted medical practices // Mayo Clinic proceedings. 2013. August. Vol. 88. № 8. P. 790–798.
Garrow J. S. How much of orthodox medicine is evidence based? // BMJ. 2007. Vol. 335. № 7627. P. 951.
Меркулова Л. Н. Колобухина Л. В., Кистенева Л. Б. и др. Терапевтическая эффективность Кагоцела при лечении больных не осложненным гриппом и гриппом, осложненным ангиной // Клиническая фармакология и терапия. 2002. Т. 11. № 6. С. 21–23.
Фазылов В. Х., Ситников И. Г., Силина Е. В., Шевченко С. Б., Можина Л. Н. и др. Лечение больных ОРВИ и гриппом в повседневной клинической практике (результаты многоцентрового международного наблюдательного исследования FLU-EE) // Терапевтический архив. 2016. Т. 88. № 11. С. 68–75.
Алиферова В. М., Дадашева М. Н., Доронин Б. М., Коваленко А. В. и др. Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта // Журнал неврологии и психиатрии им. С. С. Корсакова. 2014. Т. 114. № 4. С. 41–46.
Howes N., Chagla L., Thorpe M., McCulloch P. Surgical practice is evidence based // The British journal of surgery. 1997. September. Vol. 84. № 9. P. 1220–1223.
Kehlet H., Wilmore D. W. Multimodal strategies to improve surgical outcome // The American Journal of Surgery. 2002. Vol. 183. P. 630–641.
Kehlet H., Dahl J. B. Anaesthesia, surgery, and challenges in postoperative recovery // Lancet. 2003. Vol. 362. P. 1921–1928.
Wartolowska K., Judge A., Hopewell S., Collins G. S., Dean B. J. F. et al. Use of placebo controls in the evaluation of surgery: systematic review // BMJ. 2014. Vol. 348. № 7960, g3253.
Solomon M. J., Laxamana A., Devore L., McLeod R. S. Randomized controlled trials in surgery // Surgery. 1994. June 1. Vol. 115. № 6. P. 707–712.
Cobb L. A., Thomas G. I., Dillard D. H., Merendino K. A., Bruce R. A. An evaluation of internal-mammary-artery ligation by a double-blind technic // The New England Journal of Medicine. 1959. May 28. Vol. 260. № 22. P. 1115–1118.
Siemieniuk R. A. C., Harris I. A., Agoritsas T., Poolman R. W. et al. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline // BMJ. 2017. Vol. 357. № 8105, j1982.
Freed C. R., Greene P. E., Breeze R. E., Tsai W. Y., DuMouchel W., Kao R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease // The New England journal of medicine. 2001. March 8. Vol. 344. № 10. P. 710–719.
Tsugawa Y., Jena A. B., Newhouse R. L., Orav E. J., Blumenthal D. M. et al. Age and sex of surgeons and mortality of older surgical patients: observational study // BMJ. 2018. Vol. 361. № 8150, k1343.
Papanikolaou P. N., Churchill R., Wahlbeck K., Ioannidis J. P. A. Safety reporting in randomized trials of mental health interventions // American Journal of Psychiatry. 2004. Vol. 161. P. 1692–1697.
Smith M. L., Glass G. V. Meta-analysis of psychotherapy outcome studies // The American psychologist. 1977. September. Vol. 32. № 9. P. 752–760.
Landman J. T., Dawes R. M. Psychotherapy outcome: Smith and Glass’ conclusions stand up under scrutiny // American Psychologist. 1982. Vol. 37. № 5. P. 504–516.
Luborsky L., Singer B., Luborsky L. Comparative studies of psychotherapies: is it true that “Everyone has won and all must have prizes”? // Archives of General Psychiatry. 1975. Vol. 32. № 8. P. 995–1008.
Strupp H. H., Hadley S. W. Specific vs nonspecific factors in psychotherapy. A controlled study of outcome // Archives of general psychiatry. 1979. September. Vol. 36. № 10. P. 1125–1136.
Bootzin R. R., Bailey E. T. Understanding placebo, nocebo, and iatrogenic treatment effects // Journal of clinical psychology. 2005. uly. Vol. 61. № 7. P. 871–880.
Butler A. C., Chapman J. E., Forman E. M., Beck A. T. The empirical status of cognitive-behavioral therapy: A review of meta-analyses // Clinical Psychology Review. 2006. Vol. 26. P. 17–31.
Tolin D. F. Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review // Clinical Psychology Review. Vol. 30. № 6. P. 710–720.
Barth J., Munder T., Gerger H., Nesch E., Trelle S., Znoj H. et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis // PLoS Med. 2013. Vol. 10. № 5, e1001454.
Mayo-Wilson E., Dias S., Mavranezouli I., Kew K. et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis // Lancet Psychiatry. 2014. Vol. 1. № 5. P. 368–376.
Marcus D. K., O’Connell D., Norris A. L., Sawaqdeh A. Is the Dodo bird endangered in the 21st century? A meta-analysis of treatment comparison studies // Clinical Psychology Review. 2014. November. Vol. 34. № 7. P. 519–530.
Wampold B. E., Flckiger C., Del Re A. C., Yulish N. E., Frost N. D., Pace B. T. et al In pursuit of truth: A critical examination of meta-analyses of cognitive behavior therapy // Psychotherapy Research. 2017. Vol. 27. № 1. P. 14–32.
Van Emmerik A. A. P., Kamphuis J. H, Hulsbosch A. M., Emmelkamp P. M. G. Single session debriefing after psychological trauma: a meta-analysis // Lancet. 2002. September 07. Vol. 360. № 9335. P. 766–771.
Rose S., Brewin C. R., Andrews B., Kirk M. A randomized controlled trial of individual psychological debriefing for victims of violent crime // Psychological Medicine. 1999. July. Vol. 29. № 4. P. 793–799.
Roberts N. P., Kitchiner N. J., Kenardy J., Bisson J. I. Multiple session early psychological interventions for the prevention of posttraumatic stress disorder // Cochrane Database of Systematic Reviews. 2009. № 3. Art. № CD006869. Coulter I. D., Willis E. M. The rise and rise of complementary and alternative medicine: a sociological perspective // MJA. 2004. June 7. Vol. 180. P. 587–589.
Sampson W. Antiscience trends in the rise of the “alternative medicine” movement // Annals of the New York Academy of Sciences. 1996. June 24. Vol. 775. P. 188–197.
Eisenberg D. M., Davis R. B., Ettner S. L. et al. Trends in alternative medicine use in the United States, 1990–1997 // JAMA. 1998. Vol. 280. № 18. P. 1569–1575.
Murray J., Shepherd S. Alternative or additional medicine? An exploratory study in general practice // Social science & medicine. 1993. Vol. 37. № 8. P. 983–988.
Homeopathic Medicine & Advertising: An FTC Workshop Comments of the American Association of Homeopathic Pharmacists. 2015. November 20.
DSM Group: гомеопатические препараты занимают менее 1% рынка лекарств России // Фармацевтический вестник. 2017. 6 февраля.
Mathie R. T., Frye J., Fisher P. Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness // Cochrane Database of Systematic Reviews. 2015. № 1. Art. № CD001957.
Pakpoor J. Homeopathy is not an effective treatment for any health condition, report concludes // 2015. Vol. 350. № 8000, h1478.
Носырев И. Гомеопатия как искусство и выгодное дело // Коммерсантъ Деньги. 07.11.2016. №.44. C. 24.
Kim S., Cha J. M., Lee C. H., Shin H. P., Park J. J., Joo K. R., Lee J. I. et al. Rectal perforation due to benign stricture caused by rectal burns associated with hot coffee enemas // Endoscopy. 2012. Vol. 44. Suppl 2. UCTN: E32–3.
Shils M. E., Hermann M. G. Unproved dietary claims in the treatment of patients with cancer // Bulletin of the New York Academy of Medicine. 1982. April. Vol. 58. № 3. P. 323–340.
Eisele J. W., Reay D. T. Deaths related to coffee enemas // JAMA. 1980. Vol. 244. № 14. P. 1608–1609.
Margolin K. A., Green M. R. Polymicrobial enteric septicemia from coffee enemas // The Western journal of medicine. 1984. March. Vol. 140. № 3. P. 460.
Bogdanich W. Chinese chemicals flow unchecked onto world drug market // The New York Times. 2007. October 31.
Yang D. L. Regulatory learning and its discontents in China: promise and tragedy at the state food and drug administration / Gillespie J., Peerenboom R. (eds.) Pushing Back Globalization. Routledge, 2009.
Patwardhan B., Warude D., Pushpangadan P., Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview // Evidence-based complementary and alternative medicine. 2005. December. Vol. 2. № 4. P. 465–473.
Deadman P., Al-Khafaji M. Some acupuncture points which treat disorders of blood // Journal of Chinese Medicine. 1998. January. № 56. P. 5–18.
Rudic J. S., Poropat G., Krstic M. N., Bjelakovic G., Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis // Cochrane Database of Systematic Reviews. 2012. № 12. Art. № CD000551.
Vickers A., Goyal N., Harland R., Rees R. Do certain countries produce only positive results? A systematic review of controlled trials // Controlled clinical trials. 1998. April. Vol. 19. № 2. P. 159–166.
Colquhoun D., Novella S. P. Acupuncture is theatrical placebo // Anesthesia and analgesia. 2013. June. Vol.116. № 6. P. 1360–1363.
Topping A. Chinese use acupuncture anesthetic in heart surgery // The New York Times. 1971. May 24.
Ernst E., Lee M. S., Choi T. Y. Acupuncture: does it alleviate pain and are there serious risks? A review of reviews // Pain. 2011. April. Vol. 152. № 4. P. 755–764.
Deare J. C., Zheng Z., Xue C. C. L., Liu J. P., Shang J., Scott S. W., Littlejohn G. Acupuncture for treating fibromyalgia // Cochrane Database of Systematic Reviews. 2013. № 5. Art. № CD007070.
Manheimer E., Cheng K., Linde K., Lao L., Yoo J., Wieland S. et al. Acupuncture for peripheral joint osteoarthritis // Cochrane Database of Systematic Reviews. 2010. January 20. № 1. Art. № CD001977.
Madsen M. V., Gtzsche P. C. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups // BMJ. 2009. Vol. 338. № 7690, a3115.
Linde K., Allais G., Brinkhaus B., Manheimer E., Vickers A., White A. R. Acupuncture for migraine prophylaxis // Cochrane Database of Systematic Reviews. 2009. № 1. Art. № CD001218.
Cherkin D. C., Sherman K. J., Avins A. L. et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain // Archives of internal medicine. 2009. Vol. 169. № 9. P. 858–866.
Suarez-Almazor M. E., Looney C., Liu Y., Cox V., Pietz K. et al. A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of patient-provider communication // Arthritis care & research. 2010. September. Vol. 62. № 9. P. 1229–1236.
Dincer F., Linde K. Sham interventions in randomized clinical trials of acupuncture – a review // Complementary Therapies in Medicine. 2003. December. Vol. 11. № 4. P. 235–242.
Byard R. W., Musgrave I., Maker G., Bunce M. What risks do herbal products pose to the Australian community? // The Medical journal of Australia. 2017. Vol. 206. № 2. P. 86–90.
Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines // Trends in Pharmacological Sciences. 2002. March 1. Vol. 23. № 3. P. 136–139.
Pittler M. H., Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products // Alimentary pharmacology & therapeutics. 2003. Vol. 18. № 5. P. 451–471.
Tanaka A., Nishida R., Yoshida T., Koshikawa M., Goto M., Kuwahara T. Outbreak of Chinese herb nephropathy in Japan: are there ay differences from Belgium? // Internal medicine (Tokyo, Japan). 2001. April. Vol. 40. № 4. P. 296–300.
Zhang D., Yin P., Freemantle N., Jordan R., Zhong N., Cheng K. K. An assessment of the quality of randomised controlled trials conducted in China // Trials. 2008. April. Vol. 9. P. 22.
Gang Wang, Bing Mao, Ze-Yu Xiong, Tao Fan, Xiao-Dong Chen et al. The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China // Clinical Therapeutics. 2007. Vol. 29. № 7. P. 1456–1467.
Astin J. A. Why patients use alternative medicine: results of a national study // JAMA. 1998. Vol. 279. № 19. P. 1548–1553.
Култер К. P. Портреты гомеопатических препаратов. M.: Гомеопатическаямедицина, 2004.
Naidu K. A. Vitamin C in human health and disease is still a mystery? An overview // Nutrition Journal. 2003. Vol. 2. P. 7.
Pauling L. Are recommended daily allowances for vitamin C adequate? // PNAS. 1974. November. Vol. 71. № 11. P. 4442–4446.
Offit P. The vitamin myth: Why we think we need supplements // The Atlantic. 2013. July 19.
Anderson T. W. Reid D. B. W., Beaton G. H. Vitamin C and the common cold: a double-blind trial // Canadian Medical Association Journal. 1972. Vol. 107. № 6. P. 503–508.
Anderson T. W., Stiranyi G., Beaton G. H. The effect on winter illness of large doses of vitamin C // Canadian Medical Association Journal. 1974. Vol. 111. P. 31–36.
Anderson T. W. Large-scale trials of vitamin C // Annals of the New York Academy of Sciences. 1975. Vol. 258. P. 498–504.
Anderson T. W., Beaton G. H., Corey P., Spero L. Winter illness and vitamin C: the effect of relatively low doses // Canadian Medical Association Journal. 1975. Vol. 112. № 7. P. 823–826.
Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer // Proceedings of the National Academy of Sciences of the United States of America. 1976. October. Vol. 73. № 10. P. 3685–3689.
Hemil H., Chalker E. Vitamin C for preventing and treating the common cold // Cochrane Database of Systematic Reviews. 2013. № 1. Art. № CD000980.
Iacopetta K., Collins-Praino L. E., Buisman-Pijlman F. T. A., Liu J. et al. Are the protective benefits of vitamin D in neurodegenerative disease dependent on route of administration? A systematic review // Nutritional Neuroscience. 2018. July. Vol. 9. P. 1–30.
Allan G. M., Cranston L., Lindblad A., McCormack J., Kolber M. R. et al. Vitamin D: A narrative review examining the evidence for ten beliefs // Journal of General Internal Medicine. 2016. July. Vol. 31. № 7. P. 780–791.
Bjelakovic G., Gluud L., Nikolova D., Whitfield K., Wetterslev J. et al. Vitamin D supplementation for prevention of mortality in adults // Cochrane Database of Systematic Reviews. 2014. № 1. Art. № CD007470.
Macpherson H., Pipingas A., Pase M. P. Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials // The American journal of clinical nutrition. 2013. February. Vol. 97. № 2. P. 437–444.
The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers // The New England Journal of Medicine. 1994. April 14. Vol. 330. P. 1029–1035.
Bjelakovic G., Nikolova D., Simonetti R. G., Gluud C. Antioxidant supplements for preventing gastrointestinal cancers // Cochrane Database of Systematic Reviews. 2008. July. Vol. 16. № 3, CD004183.
Omenn G. S., M. D., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease // The New England Journal of Medicine. 1996. May 2. Vol. 334. P. 1150–1155.
Miller E. R., Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J. et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality // Annals of Internal Medicine. 2005. Vol. 142. № 1. P. 37–46.
Dyerberg J. Coronary heart disease in Greenland Inuit: a paradox. Implications for western diet patterns // Arctic medical research. 1989. April. Vol. 48. № 2. P. 47–54.
Abdelhamid A. S., Brown T. J., Brainard J. S., Biswas P., Thorpe G. C. et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease // Cochrane Database of Systematic Reviews. 2018. № 7. Art. № CD003177.
Kwak S. M., Myung S. K., Lee Y. J., Seo H. G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials // Archives of internal medicine. 2012. May 14. Vol. 172. № 9. P. 686–694.
Rizos E. C., Ntzani E. E., Bika E., Kostapanos M. S., Elisaf M. S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis // JAMA. 2012. September 12. Vol. 308. № 10. P. 1024–1033.
Aung T., Halsey J., Kromhout D. et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks. Meta-analysis of 10 trials involving 77 917 individuals // JAMA Cardiology. 2018. Vol. 3. № 3. P. 225–233.
Bhatt D. L., Steg P. G., Miller M., Brinton E. A., Jacobson T. A. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia // The New England Journal of Medicine. 2019. January 3. Vol. 380. P. 11–22.
Manson J. E., Cook N. R., I – Min Lee, Christen W., Bassuk S. S. et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer // The New England Journal of Medicine. 2019. January 3. Vol. 380. P. 23–32.
Carroll A. E. Given Their Potential for Harm, It’s Time to Focus on the Safety of Supplements // JAMA. 2018. Vol. 320. № 13. P. 1306–1307.
Newmaster S. G., Grguric M., Shanmughanandhan D., Ramalingam S., Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products // BMC medicine. 2013. Vol. 11. № 1. P. 222.
Harmon K. Herbal supplement sellers dispense dangerous advice, false claims // Scientific American. 2010. May 28.